Mechanisms of Tissue Uptake and Retention in Zotarolimus-Coated Balloon Therapy

1Harvard-MIT Division of Health Sciences and Technology & Charles Stark Draper Laboratory, Cambridge, MA.
Circulation (Impact Factor: 14.43). 04/2013; DOI: 10.1161/CIRCULATIONAHA.113.002051
Source: PubMed


Drug-coated balloons are increasingly used for peripheral vascular disease, and, yet, mechanisms of tissue uptake and retention remain poorly characterized. Most systems to date have used paclitaxel, touting its propensity to associate with various excipients that can optimize its transfer and retention. We examined zotarolimus pharmacokinetics.

Methods and results:
Animal studies, bench-top experiments, and computational modeling were integrated to quantify arterial distribution after zotarolimus-coated balloon use. Drug diffusivity and binding parameters for use in computational modeling were estimated from the kinetics of zotarolimus uptake into excised porcine femoral artery specimens immersed in radiolabeled drug solutions. Like paclitaxel, zotarolimus exhibited high partitioning into the arterial wall. Exposure of intimal tissue to drug revealed differential distribution patterns, with zotarolimus concentration decreasing with transmural depth as opposed to the multiple peaks displayed by paclitaxel. Drug release kinetics was measured by inflating zotarolimus-coated balloons in whole blood. In vivo drug uptake in swine arteries increased with inflation time but not with balloon size. Simulations coupling transmural diffusion and reversible binding to tissue proteins predicted arterial distribution that correlated with in vivo uptake. Diffusion governed drug distribution soon after balloon expansion, but binding determined drug retention.

A large bolus of zotarolimus releases during balloon inflation, some of which pervades the tissue, and a fraction of the remaining drug adheres to the tissue-lumen interface. As a result, the duration of delivery modulates tissue uptake where diffusion and reversible binding to tissue proteins determine drug transport and retention, respectively.


Available from: Vijaya B. Kolachalama
  • Source
    • "While drug molecules diffuse within the arterial wall, various drug-tissue interactions occur that affect the arterial wall drug transport, distribution, and drug uptake [40] [41]. The drug-arterial wall interaction has been commonly modeled as a reversible binding reaction of the drug molecules with binding sites present in the arterial wall, as shown in Eq. (5) [22] [24] [27] [41]. In the process, bound drug C B is formed by associating free drug C F with the available binding sites S. The bound drug is immobilized and only the free drug can diffuse. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Increasing interests have been raised towards the potential applications of biodegradable poly(lactic-co-glycolic acid) (PLGA) coatings for drug-eluting stents in order to improve the drug delivery and reduce adverse outcomes in stented arteries in patients. This article presents a mathematical model to describe the integrated processes of drug release in a stent with PLGA coating and subsequent drug delivery, distribution, and drug pharmacokinetics in the arterial wall. The model takes into account the PLGA degradation and erosion, anisotropic drug diffusion in the arterial wall, reversible drug binding, and drug internalization. After comparing simulation results for a biodegradable PLGA coating with a biodurable coating for stent-based drug delivery, the simulations further investigate drug internalization, interstitial fluid flow in the arterial wall, and stent embedment for their impact on drug release in the PLGA coating, arterial drug levels, and arterial drug distribution. It is shown that these three factors, while imposing little change in the drug release profiles, can greatly change the average drug concentrations in the arterial wall. In particular, each of the factors leads to significant and yet distinguished alterations in the arterial drug distribution that can potentially influence the treatment outcomes. The detailed integrated model provides insights into the design and evaluation of biodegradable PLGA-coated drug-eluting stents for improved intravascular drug delivery.
    Journal of Biomechanical Engineering 08/2014; 136(11). DOI:10.1115/1.4028135 · 1.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nonstent-based local drug delivery during percutaneous intervention offers potential for sustained antirestenotic efficacy without the limitations of permanent vascular implants. Preclinical studies have shown that effective local tissue concentrations of drugs can be achieved using drug-coated balloon (DCB) catheters. Matrix coatings consisting of a mixture of lipophilic paclitaxel and hydrophilic spacer (excipient) are most effective. Clinical applications most suited to DCB therapy are those for which stent implantation is not desirable or less effective, such as in-stent restenosis, bifurcation lesions, or peripheral artery stenoses. Randomized trials have shown superiority of DCBs over plain-balloon angioplasty for both bare-metal and drug-eluting coronary in-stent restenosis, and similar efficacy as repeat stenting with a drug-eluting stent (DES). Bycontrast, randomized trials of DCBs in de novo coronary stenosis have, to date, not shown similar efficacy to standard-of-care DES therapy. In peripheral artery disease, DCB therapy has proven superior to plain-balloon angioplasty for treatment of de novo femoropoliteal and below-the-knee disease, and shown promising results for in-stent restenosis. Overall, however, despite many years of clinical experience with DCBs, the number of large, high-quality, randomized clinical trials is low, and further data are urgently needed across the spectrum of clinical indications.
    Nature Reviews Cardiology 11/2013; 11(1). DOI:10.1038/nrcardio.2013.165 · 9.18 Impact Factor

  • Circulation 12/2013; 128(24):e461. DOI:10.1161/CIRCULATIONAHA.113.002591 · 14.43 Impact Factor
Show more